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ventricular ejection fraction of 65%, mild left 
atrial enlargement (42 mm/24 cm2), and dilata‑
tion of the ascending aorta (53 mm) confirmed 
by computed tomography angiography. In July 
2019, after 15 months on ibrutinib, he reported 
palpitations and persistent AF was diagnosed. 
Ibrutinib was withheld, and bisoprolol 5 mg/d 
and dabigatran 150 mg twice daily were admin‑
istered. In September 2019, electrical cardio‑
version was successfully performed, ibrutinib 
was resumed, and dabigatran reduced to 110 mg 
twice daily. After 2 weeks, dabigatran concentra‑
tion was measured using a commercially avail‑
able Innovance diluted thrombin time (dTT) 
assay (Siemens Healthcare Diagnostics GmbH, 
Erlangen, Germany). Blood samples were tak‑
en 3 hours after dabigatran administration (ap‑
proximately at its peak concentration) and at 12 
hours (trough level). During the 6‑month follow‑
‑up, sinus rhythm was maintained and no bleed‑
ing complications were reported.
The second patient, a 70‑year ‑old man with 
CLL since 1998, started receiving ibrutinib 
at a standard dose of 420 mg/d in March 2018. 
At that time, the patient had hypertension, heart 
failure (New York Heart Association class II), 
permanent AF (since 2009, with no attempts 
to restore sinus rhythm), chronic renal failure, 
and hypercholesterolemia. Cardiac assessment 
before starting ibrutinib showed good control 
of hypertension (telmisartan 80 mg/d and to‑
rasemide 2.5 mg/d) and heart rate (bisoprolol 
Introduction Ibrutinib is an irreversible Bru‑
ton tyrosine kinase inhibitor, which is approved 
for the treatment of chronic lymphocytic leuke‑
mia (CLL), Waldenström macroglobulinemia, 
and mantle cell lymphoma and is associated with 
significant improvement in patient outcomes.1 
However, ibrutinib is related to risk of atrial fi‑
brillation (AF) ranging from 4% to 16%.2,3 Man‑
agement of AF in patients receiving ibrutinib is 
challenging due to numerous drug interactions. 
Moreover, ibrutinib inhibits platelet aggregation 
and increases the risk of bleeding, even without 
concomitant use of aspirin or anticoagulants,4 
which makes the decision about stroke preven‑
tion more complex.5,6 Direct oral anticoagulants 
(DOACs) have been shown to be at least nonin‑
ferior to warfarin in the prevention of systemic 
embolism in patients with AF and to carry low‑
er bleeding risk.7 In the case of dabigatran, it is 
possible to monitor its plasma concentration, 
which may be useful in some clinical situations. 
Nevertheless, current data regarding combina‑
tion of DOACs and ibrutinib are insufficient to 
draw firm conclusions, and each case should be 
assessed individually.6,8
Methods A 71‑year ‑old man with CLL since 
2009 and hypertension started receiving ibruti‑
nib at a standard dose of 420 mg/d in April 2018. 
No history of AF was documented, and hy‑
pertension was well ‑controlled (perindopril 
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rituximab), the patient developed bruising and 
minor bleedings. No anticoagulation was pre‑
scribed until October 2018, when dabigatran was 
administered at a dose of 110 mg twice daily. As 
mild bruising occurred, dabigatran was reduced 
2.5 mg/d). Echocardiography revealed reduced 
left ventricular ejection fraction of 43% and sig‑
nificant left atrial enlargement (55 mm/32 cm2). 
As under previous chemotherapy (chlorambu‑
cil, then fludarabine, cyclophosphamide, and 
TABLE 1 Patients’ characteristics and laboratory parameters at the time of plasma dabigatran concentration 
measurement
Parameter Patient 1 Patient 2
Age, y 71 70
RAI stage 1 3
Therapies before ibrutinib 1 3
FISH del17 del17
Body mass index, kg/m2 27 27
Hypertension Yes Yes
Renal failure No Yes
Smoking status No No
History of AF No Yes (permanent)
Time since CLL diagnosis, y 11 21
Ibrutinib and dabigatran treatment duration, mo 6 16
CHA2DS2‑VASc 2 3
HAS ‑BLEDa 1 (2) 3 (4)
First dabigatran concentration measurement
Hemoglobin, g/dl 15.1 14.6
Platelet count, × 109/µl 124 179
Creatinine, mg/dl 0.93 1.66
Glomerular filtration rate, ml/min/1.73 m2 82 38
Ibrutinib dose, mg 280 280
Dabigatran dose, mg 110 twice daily 110 once daily
Trough dabigatran concentration, ng/ml 64 48
Peak dabigatran concentration, ng/ml 130 145
Second dabigatran concentration measurementb
Hemoglobin, g/dl 14.8 14.5
Platelet count, × 109/µl 118 184
Creatinine, mg/dl 0.93 1.54
Glomerular filtration rate, ml/min/1.73 m2 82 45
Ibrutinib dose, mg 280 140
Dabigatran dose, mg 110 twice daily 110 once daily
Trough dabigatran concentration, ng/ml 36 38
Peak dabigatran concentration, ng/ml 95 121
a The score result after including dabigatran treatment
b Two months after the previous measurement
Conversion factors to SI units: to convert creatinine to μmol/l, multiply by 88.4.
Abbreviations: AF, atrial fibrillation; CHA2DS2‑VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of 
stroke or thromboembolism, vascular disease, age 65 to 74 years, female sex; CLL, chronic lymphocytic leukemia; FISH, fluorescence in 
situ hybridization; HAS‑BLED, uncontrolled hypertension, abnormal liver or renal function, history of stroke or thromboembolism, 
history of bleeding, age ≥65 years, use of nonsteroidal anti‑inflammatory drugs, and alcohol abuse
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tests are not specific for DOACs, and the results 
depend on the type of the reagent used for test‑
ing. The aPTT gives only quantitative informa‑
tion about the presence of dabigatran and may 
be nonprolonged if a reagent used for its assess‑
ment is not sensitive enough.12 The dTT assay is 
the best qualitative method to evaluate the an‑
ticoagulant effects of dabigatran and, based on 
that, calculate dabigatran plasma concentration. 
In both our patients treated with ibrutinib, we 
evaluated dabigatran concentration at its trough 
and peak levels and it was within the therapeu‑
tic range of values indicated by the laboratory. 
Nevertheless, a reference therapeutic range for 
dabigatran to mitigate the risk of both throm‑
boembolic events and bleeding has not been 
determined yet. However, it has been suggest‑
ed that a trough dTT longer than 65 s (corre‑
sponding to the dabigatran concentration of 
200 ng/ml) is associated with a higher bleed‑
ing risk.13 No stroke nor bleeding events were 
reported during the mean 11.5‑month follow‑
‑up, and remission of CLL was observed in both 
patients. Thus, follow ‑up examinations demon‑
strated that the drug concentration was effec‑
tive and safe during the ibrutinib therapy, also 
in the patient with renal impairment. Because 
the patients’ clinical condition was stable, and 
their treatment remained unchanged, no fur‑
ther measurements of dabigatran concentra‑
tion were performed.
In this study, we showed that the use of dab‑
igatran at its controlled plasma concentration 
helps prevent stroke in patients with AF treated 
with ibrutinib. This approach allows clinicians 
to evaluate the anticoagulant activity and may 
improve the safety of anticoagulation.
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to 110 mg/d. After 2 weeks, dabigatran concen‑
tration was assessed at its peak and trough lev‑
els: 3 and 23 hours after dabigatran admin‑
istration, respectively. During the 16‑month 
follow ‑up, no new bleeding complications were 
reported.
The study on ibrutinib use in AF was approved 
by the local ethics committee, and all study par‑
ticipants provided written informed consent.
Results and discussion Clinical characteris‑
tics of the study patients are presented in TABLE 1, 
which also shows laboratory parameters at the 
time when plasma dabigatran concentration 
was measured.
Ibrutinib has a favorable toxicity profile, but 
increased severity of arrhythmia, AF in partic‑
ular, and bleeding risk due to its use have been 
reported.4,9 In a retrospective study, which in‑
cluded 582 patients treated with ibrutinib for 
hematologic malignancies, 76 individuals de‑
veloped AF, and the estimated cumulative inci‑
dence of AF at 6 months, 1 year, and 2 years was 
5.9%, 7.5%, and 10.3%, respectively. There were 
9 major bleedings in 7 patients and 34 clinical‑
ly relevant nonmajor bleedings in 24 patients.3
In patients with nonvalvular AF, oral antico‑
agulation is limited to DOACs and warfarin, but 
DOACs are preferred over warfarin due to their 
safety and noninferiority in stroke prevention.7 
Warfarin is metabolized primarily by the hepat‑
ic CYP2C9 enzyme, thus ibrutinib should have 
no pharmacokinetic interactions, as opposed 
to DOACs. The anticoagulant effect of warfarin 
has the advantage of easy reversal, but warfa‑
rin is associated with a higher risk of intracra‑
nial bleeding compared with DOACs.9
Ibrutinib is metabolized by the  hepatic 
 CYP3A4 cytochrome, which also applies to riva‑
roxaban and apixaban. Competition for CYP3A4 
between ibrutinib and these DOACs, leading to 
unpredictable plasma levels of 1 agent or anoth‑
er, may increase the bleeding risk.9
Ibrutinib is a P ‑glycoprotein inhibitor and 
may increase serum DOAC concentrations, 
which can be clinically significant in the pres‑
ence of renal failure, particularly for dabiga‑
tran due to its mainly renal (80%) elimination.
Nevertheless, among the available DOACs, 
dabigatran appears to be the most suitable drug, 
as it does not interact with the cytochrome P450 
system, has an effective antidote, and its plas‑
ma levels can be monitored.7,10 Idarucizumab is 
a specific reversal agent for dabigatran in pa‑
tients who develop life ‑threatening bleeding.7 
Regarding coagulation tests, at therapeutic plas‑
ma levels, dabigatran prolongs the activated par‑
tial thromboplastin time (aPTT), and also has 
a slight effect on the prothrombin time.11 Of note, 
basic coagulation tests, such as aPTT and pro‑
thrombin time, should not be performed to as‑
sess the anticoagulant effects of DOACs. These 
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